Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Joanne E. Compson is active.

Publication


Featured researches published by Joanne E. Compson.


Journal of Biological Chemistry | 2012

Characterization of the Interaction of Sclerostin with the Low Density Lipoprotein Receptor-related Protein (LRP) Family of Wnt Co-receptors

Gill Holdsworth; Patrick M. Slocombe; Carl Doyle; Bernadette Sweeney; Vaclav Veverka; Kelly Le Riche; Richard Jeremy Franklin; Joanne E. Compson; Daniel Christopher Brookings; James M. A. Turner; Jeffery Kennedy; Rachael Garlish; Jiye Shi; Laura E Newnham; David McMillan; Mariusz Muzylak; Mark D. Carr; Alistair J. Henry; Thomas Allen Ceska; Martyn K. Robinson

Background: Sclerostin, an inhibitor of Wnt signaling, binds to the β-propeller domain-containing Wnt co-receptors LRP6 and LRP4. Results: An NXI motif in sclerostin mediates interactions with LRP6 (but not LRP4) and blocks Wnt1 signaling. Conclusion: The sclerostin/LRP6 interaction shares features with the well characterized nidogen/laminin interaction. Significance: NXI motifs are important in mediating interactions with β-propeller containing proteins. LRP5 and LRP6 are proteins predicted to contain four six-bladed β-propeller domains and both bind the bone-specific Wnt signaling antagonist sclerostin. Here, we report the crystal structure of the amino-terminal region of LRP6 and using NMR show that the ability of sclerostin to bind to this molecule is mediated by the central core of sclerostin and does not involve the amino- and carboxyl-terminal flexible arm regions. We show that this structured core region interacts with LRP5 and LRP6 via an NXI motif (found in the sequence PNAIG) within a flexible loop region (loop 2) within the central core region. This sequence is related closely to a previously identified motif in laminin that mediates its interaction with the β-propeller domain of nidogen. However, the NXI motif is not involved in the interaction of sclerostin with LRP4 (another β-propeller containing protein in the LRP family). A peptide derived from the loop 2 region of sclerostin blocked the interaction of sclerostin with LRP5/6 and also inhibited Wnt1 but not Wnt3A or Wnt9B signaling. This suggests that these Wnts interact with LRP6 in different ways.


Clinical and Vaccine Immunology | 2013

A Mixture of Functionally Oligoclonal Humanized Monoclonal Antibodies That Neutralize Clostridium difficile TcdA and TcdB with High Levels of In Vitro Potency Shows In Vivo Protection in a Hamster Infection Model

Nicola L. Davies; Joanne E. Compson; Brendon MacKenzie; Victoria Odowd; Amanda Oxbrow; James Heads; Alison Turner; Kaushik Sarkar; Sarah L. Dugdale; Mark Jairaj; Louis Christodoulou; David Edward Ormonde Knight; Amanda S. Cross; Karine Jeannine Madeleine Hervé; Kerry Louise Tyson; Hanna Hailu; Carl Doyle; Mark Ellis; Marco Kriek; Matthew Cox; Matthew Page; Adrian Moore; Daniel John Lightwood; David Paul Humphreys

ABSTRACT Clostridium difficile infections are a major cause of antibiotic-associated diarrhea in hospital and care facility patients. In spite of the availability of effective antibiotic treatments, C. difficile infection (CDI) is still a major cause of patient suffering, death, and substantial health care costs. Clostridium difficile exerts its major pathological effects through the actions of two protein exotoxins, TcdA and TcdB, which bind to and disrupt gut tissue. Antibiotics target the infecting bacteria but not the exotoxins. Administering neutralizing antibodies against TcdA and TcdB to patients receiving antibiotic treatment might modulate the effects of the exotoxins directly. We have developed a mixture of three humanized IgG1 monoclonal antibodies (MAbs) which neutralize TcdA and TcdB to address three clinical needs: reduction of the severity and duration of diarrhea, reduction of death rates, and reduction of the rate of recurrence. The UCB MAb mixture showed higher potency in a variety of in vitro binding and neutralization assays (∼10-fold improvements), higher levels of protection in a hamster model of CDI (82% versus 18% at 28 days), and higher valencies of toxin binding (12 versus 2 for TcdA and 3 versus 2 for TcdB) than other agents in clinical development. Comparisons of the MAb properties also offered some insight into the potential relative importance of TcdA and TcdB in the disease process.


mAbs | 2014

The rapid generation of recombinant functional monoclonal antibodies from individual, antigen-specific bone marrow-derived plasma cells isolated using a novel fluorescence-based method

Alison M Clargo; Ashley R Hudson; Welcome Ndlovu; Rebecca Jayne Wootton; Louise A Cremin; Victoria Odowd; Carla R Nowosad; Dale Starkie; Sophie P. Shaw; Joanne E. Compson; Dominic P White; Brendon MacKenzie; James Snowden; Laura E Newnham; Michael Wright; Paul E. Stephens; Meryn Griffiths; Alastair Dg. Lawson; Daniel John Lightwood

Single B cell technologies, which avoid traditional hybridoma fusion and combinatorial display, provide a means to interrogate the naturally-selected antibody repertoire of immunized animals. Many methods enable the sampling of memory B cell subsets, but few allow for the direct interrogation of the plasma cell repertoire, i.e., the subset of B cells responsible for producing immunoglobulin in serum. Here, we describe the use of a robust and simple fluorescence-based technique, called the fluorescent foci method, for the identification and isolation of antigen-specific IgG-secreting cells, such as plasma cells, from heterogeneous bone marrow preparations. Following micromanipulation of single cells, cognate pairs of heavy and light chain variable region genes were recovered by reverse transcription (RT)-polymerase chain reaction (PCR). During the PCR, variable regions were combined with a promoter fragment and a relevant constant region fragment to produce two separate transcriptionally-active PCR (TAP) fragments that were directly co-transfected into a HEK-293F cell line for recombinant antibody expression. The technique was successfully applied to the generation of a diverse panel of high-affinity, functional recombinant antibodies to human tumor necrosis factor (TNF) receptor 2 and TNF derived from the bone marrow of immunized rabbits and rats, respectively. Progression from a bone marrow sample to a panel of functional recombinant antibodies was possible within a 2-week timeframe.


Protein Engineering Design & Selection | 2012

Towards a universal disulphide stabilised single chain Fv format: importance of interchain disulphide bond location and vL–vH orientation

Eve E. Weatherill; Katharine Cain; Sam Philip Heywood; Joanne E. Compson; James Heads; Ralph Adams; David Paul Humphreys

Engineered introduction of interface interchain disulphide bonds is perceived to be a simple method to increase the stability of single chain Fv (scFv). Six disulphide bond locations have been cited within the literature but the potential for the broad use of each has not been examined. Five of these disulphide bond locations were introduced into one scFv in order to compare their relative effects on expression, thermal stability, percent monomer formation and retention of antigen binding. The disulphide bond position vH44-vL100 was observed to enable the most favourable balance of biophysical properties. The vH44-vL100 disulphide bond was introduced into five additional scFv in both vL-vH and vH-vL orientations in order to investigate its general applicability. Data are presented to show the relative influence of scFv sequence, v-region organisation and interchain disulphide bond on expression yield, thermal stability and percent monomer. Introduction of the vH44-vL100 disulphide bond typically resulted in no or little increase in thermal stability and no change in percent monomer but did confer the benefit of permanently fixing monomer:dimer ratios during purification and analysis.


PLOS ONE | 2016

Generation of Recombinant Monoclonal Antibodies from Immunised Mice and Rabbits via Flow Cytometry and Sorting of Antigen-Specific IgG+ Memory B Cells

Dale Starkie; Joanne E. Compson; Stephen Edward Rapecki; Daniel John Lightwood

Single B cell screening strategies, which avoid both hybridoma fusion and combinatorial display, have emerged as important technologies for efficiently sampling the natural antibody repertoire of immunized animals and humans. Having access to a range of methods to interrogate different B cell subsets provides an attractive option to ensure large and diverse panels of high quality antibody are produced. The generation of multiple antibodies and having the ability to find rare B cell clones producing IgG with unique and desirable characteristics facilitates the identification of fit-for-purpose molecules that can be developed into therapeutic agents or research reagents. Here, we describe a multi-parameter flow cytometry single-cell sorting technique for the generation of antigen-specific recombinant monoclonal antibodies from single IgG+ memory B cells. Both mouse splenocytes and rabbit PBMC from immunised animals were used as a source of B cells. Reagents staining both B cells and other unwanted cell types enabled efficient identification of class-switched IgG+ memory B cells. Concurrent staining with antigen labelled separately with two spectrally-distinct fluorophores enabled antigen-specific B cells to be identified, i.e. those which bind to both antigen conjugates (double-positive). These cells were then typically sorted at one cell per well using FACS directly into a 96-well plate containing reverse transcriptase reaction mix. Following production of cDNA, PCR was performed to amplify cognate heavy and light chain variable region genes and generate transcriptionally-active PCR (TAP) fragments. These linear expression cassettes were then used directly in a mammalian cell transfection to generate recombinant antibody for further testing. We were able to successfully generate antigen-specific recombinant antibodies from both the rabbit and mouse IgG+ memory B cell subset within one week. This included the generation of an anti-TNFR2 blocking antibody from mice with an affinity of 90 pM.


mAbs | 2016

Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: An investigation into the correlation between affinity and serum half-life

Ralph Adams; Laura Griffin; Joanne E. Compson; Mark Jairaj; Terry Baker; Tom Ceska; Shauna West; Oliver Zaccheo; Emma Dave; Alastair Dg. Lawson; David Paul Humphreys; Sam Philip Heywood

ABSTRACT We generated an anti-albumin antibody, CA645, to link its Fv domain to an antigen-binding fragment (Fab), thereby extending the serum half-life of the Fab. CA645 was demonstrated to bind human, cynomolgus, and mouse serum albumin with similar affinity (1–7 nM), and to bind human serum albumin (HSA) when it is in complex with common known ligands. Importantly for half-life extension, CA645 binds HSA with similar affinity within the physiologically relevant range of pH 5.0 – pH 7.4, and does not have a deleterious effect on the binding of HSA to neonatal Fc receptor (FcRn). A crystal structure of humanized CA645 Fab in complex with HSA was solved and showed that CA645 Fab binds to domain II of HSA. Superimposition with the crystal structure of FcRn bound to HSA confirmed that CA645 does not block HSA binding to FcRn. In mice, the serum half-life of humanized CA645 Fab is 84.2 h. This is a significant extension in comparison with < 1 h for a non-HSA binding CA645 Fab variant. The Fab-HSA structure was used to design a series of mutants with reduced affinity to investigate the correlation between the affinity for albumin and serum half-life. Reduction in the affinity for MSA by 144-fold from 2.2 nM to 316 nM had no effect on serum half-life. Strikingly, despite a reduction in affinity to 62 µM, an extension in serum half-life of 26.4 h was still obtained. CA645 Fab and the CA645 Fab-HSA complex have been deposited in the Protein Data Bank (PDB) with accession codes, 5FUZ and 5FUO, respectively.


Arthritis & Rheumatism | 2018

Human plasma cell derived monoclonal antibodies to post-translationally modified proteins recognize amino acid motifs rather than specific proteins

Johanna Steen; Björn Forsström; Peter Sahlström; Victoria Odowd; Lena Israelsson; Akilan Krishnamurthy; Sara Badreh; Linda Mathsson Alm; Joanne E. Compson; Daniel Ramsköld; Welcome Ndlovu; Stephen Edward Rapecki; Monika Hansson; Philip J. Titcombe; Holger Bang; Daniel L. Mueller; Anca Irinel Catrina; Caroline Grönwall; Karl Skriner; Peter Nilsson; Daniel John Lightwood; Lars Klareskog; Vivianne Malmström

Antibodies against posttranslationally modified proteins are a hallmark of rheumatoid arthritis (RA), but the emergence and pathogenicity of these autoantibodies are still incompletely understood. The aim of this study was to analyze the antigen specificities and mutation patterns of monoclonal antibodies (mAb) derived from RA synovial plasma cells and address the question of antigen cross‐reactivity.


Archive | 2012

Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile

David Paul Humphreys; Daniel John Lightwood; Kerry Louise Tyson; David Edward Ormonde Knight; Karine Jeannine Madeleine Hervé; Joanne E. Compson; Matthew Page; Andrew Payne; Nicola Louise Fisher; Brendon MacKenzie; Matthew Cox


mAbs | 2016

Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding

Emma Dave; Ralph Adams; Oliver Zaccheo; Bruce Carrington; Joanne E. Compson; Sarah L. Dugdale; Michael Airey; Sarah Malcolm; Hanna Hailu; Gavin Barry Wild; Alison Turner; James Heads; Kaushik Sarkar; Andrew Ventom; Diane Marshall; Mark Jairaj; Tim Kopotsha; Louis Christodoulou; Miren Zamacona; Alastair David Griffiths Lawson; Sam Philip Heywood; David Paul Humphreys


Archive | 2017

anticorpos capazes de neutralizar as exotoxinas principais tcda e tcdb de clostridium difficile

Andrew Payne; Brendon MacKenzie; Daniel John Lightwood; David Edward Ormonde Knight; David Paul Humphreys; Joanne E. Compson; Karine Jeannine Madeleine Hervé; Kerry Louise Tyson; Matthew Cox; Matthew Page; Nicola Louise Fisher

Researchain Logo
Decentralizing Knowledge